blog
FDA enforcement analysis
Sourced, dated analysis for compliance and regulatory affairs teams.
2026-07-12
What is an FDA Warning Letter Close-Out Letter?
It confirms one Warning Letter's citations were corrected — it doesn't retract the letter, and most corrected Warning Letters never get one at all. How the close-out process actually works, and why a missing letter isn't an open compliance flag.
Read more →2026-07-12
Is FDA's new device quality rule a compliance reset? The first warning letters say no
FDA's QMSR replaced most of 21 CFR 820 on Feb 2, 2026. A March 2026 warning letter to Medline Industries cites a QS-Regulation-era inspection and still demands a QMSR-standard fix — no grace period.
Read more →2026-07-11
Can FDA order a drug maker to never restart production?
FDA cited New Life Pharma for selling unapproved semaglutide and tirzepatide vials, zero aseptic validation, and denying inspectors access to two rooms labeled "Area Not in Use" — then told the firm not to restart manufacturing at all.
Read more →2026-07-11
What is an FDA consent decree, and how does a Warning Letter lead to one?
Pharmasol Corporation went from a 2019 Warning Letter to a December 2023 consent decree over the same unresolved CGMP failures. The step-by-step timeline from inspection to court order, and who pays once a decree is entered.
Read more →2026-07-11
Why did FDA send 13 warning letters to online ketamine sellers in a single day?
One day, one drug, 13 letters — 42% of FDA's 2026 unapproved-drug warning letters. The shared statutory pattern, the MARCS numbering that reveals a single drafting batch, and what it means for telehealth and DTC drug sellers.
Read more →2026-07-10
What's the difference between an FDA Untitled Letter and a Warning Letter?
Only one of these two FDA advisory actions contains the sentence that makes it a legal threat. How the two-tier system works, and what each one means for a compliance risk register.
Read more →2026-07-10
What actually makes an FDA warning letter response "adequate" enough to close out?
Wizcure Pharmaa suspended manufacturing, hired a consultant, and still got rejected on all four citations. An 8-point adequacy checklist built directly from FDA's own Regulatory Procedures Manual.
Read more →2026-07-09
Sato Pharmaceutical Co., Ltd. FDA Warning Letter 320-26-75 — aseptic filling CGMP violations
CDER called the firm's ISO 5 aseptic filling line "fundamentally unsuitable" after six media fill failures, plus an inadequate stability program and OTC products released without required microbiological testing — FDA rejected the response on all three citations.
Read more →2026-07-09
How to read your FDA inspection classification: NAI vs. VAI vs. OAI
A Form 483 is not your classification. Five steps to figure out where your last FDA inspection actually landed, and what OAI does (and doesn’t) mean for what happens next.
Read more →2026-07-09
Can you blame an AI agent for a CGMP violation? FDA just answered that.
FDA’s April 2, 2026 warning letter to Purolea Cosmetics Lab cites unreviewed AI-generated specifications and procedures — the first warning letter with a standalone AI-misuse section, tied to 21 CFR 211.22(c).
Read more →2026-07-08
Huons Co., Ltd. FDA Warning Letter 320-26-95 — data integrity CGMP violations
A microbiology team leader cut finished pages out of a lab logbook with a knife and replaced them with fabricated ones. FDA also found 1,897 blank uncontrolled forms and rejected the firm's CAPA plan after it withheld a promised third-party audit report.
Read more →2026-07-08
What is an FDA Import Alert, and what does DWPE mean?
FDA can detain shipments at the border without testing them, once a firm appears on an Import Alert under the FD&C Act's appearance standard. How the Red/Yellow/Green lists work, who carries the burden of proof, and how removal works.
Read more →2026-07-08
The 5 most-cited FDA warning letter violations in FY2025, ranked
21 CFR 211.22 topped the list, cited in 62 of 134 inspection-based warning letters. The full ranked breakdown of what FDA cited most, and what each citation means for a quality system.
Read more →2026-07-07
Wizcure Pharmaa FDA Warning Letter 320-26-97 — sterile CGMP violations
"Original plates were discarded and replaced with new plates." CDER cited the Bhiwadi, India sterile manufacturer for a fabricated microbial-plate result, a missing ISO 5/ISO 7 barrier, deficient media fills, and rusted aseptic equipment — FDA found the response inadequate on all four citations.
Read more →2026-07-07
What's the difference between a Form 483 and an FDA Warning Letter?
A Form 483 is a field-issued inspection note. A Warning Letter is a later, headquarters-reviewed legal notice. Why most 483s never escalate, and why Warning Letter counts alone understate FDA enforcement activity.
Read more →2026-07-07
FDA proposes to exclude semaglutide and tirzepatide from the 503B Bulks List
FDA's April 30, 2026 proposal would permanently bar 503B outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk API. The comment period closed June 29 with 4,000+ submissions — here's the clinical-need standard behind it.
Read more →2026-07-06
Genzyme Ireland Limited FDA Warning Letter CBER 26-728681 — biologics CGMP violations
CBER cited the Sanofi subsidiary for a quality control unit that failed to enforce CGMP, incomplete lab records including (b)(4) tests repeated up to 11 times undocumented, and deviations cancelled without root-cause investigation.
Read more →2026-07-06
Why did the FDA send Novo Nordisk a warning letter over Ozempic and Wegovy safety reporting?
FDA's March 5, 2026 warning letter names specific Argus case numbers — a stroke, a suicide, and unreported deaths — where Novo Nordisk's own procedures blocked required 15-day adverse event reports.
Read more →2026-07-06
FDA's Quality Management Maturity program, explained
FDA opened the third year of its voluntary QMM assessment on February 11, 2026. Only firms already rated No Action Indicated or Voluntary Action Indicated can apply — here is what gets scored, and the FOIA risk law firms are flagging.
Read more →2026-07-05
Pharmathen International FDA Warning Letter 320-26-80 — sterile injectable CGMP violations
CDER cited Pharmathen International S.A., Evrou, Greece, for failed airflow studies, inadequate failure investigations, and undocumented lab records — the firm suspended manufacturing and its customers recalled affected batches.
Read more →2026-07-05
What triggers an FDA Warning Letter for compounded GLP-1 marketing?
Three enforcement waves and one legal theory: marketing that implies a compounded semaglutide or tirzepatide product is FDA-approved. The exact phrases flagged, and an 8-step audit for marketing and compliance teams.
Read more →2026-07-05
How long does a company have to respond to an FDA Warning Letter?
Usually 15 working days — a norm from FDA’s Regulatory Procedures Manual, not a statute. How the clock works, how it differs from the Form 483 window, and what the March 2026 draft guidance changed.
Read more →2026-07-04
Excelvision (Fareva) FDA Warning Letter 726714 — sterile ophthalmic CGMP violations
CDER cited Excelvision (Fareva), Annonay, France, for microbial-contamination and facility failures on a sterile eye-drop line, a repeat violation now under Import Alert 66-40.
Read more →2026-07-02
Why FDA enforcement is up nearly 60% in 2026 — and what it means for your compliance team
FDA issued 303 drug Warning Letters in FY2025, up 59% from FY2024. What is driving the increase, and five practical implications for compliance teams.
Read more →